SIGA Q4 and FY25 Revenue Declines Amidst FDA Approvals and International Orders

SIGA Technologies reported a decline in revenue for Q4 and FY25, with a net loss of $5.4 million and total revenue of $3.8 million for Q4, compared to a net income of $45.7 million and total revenue of $81.4 million in the prior year. For FY25, net income slipped to $23.3 million from $59.2 million, and total revenue decreased to $94.57 million from $138.72 million. The firm's lead commercial product, TPOXX, saw a decline in product-based revenue to $88.05 million from $133.33 million in the year-ago period.